Gautam Mehta et al. summarize the FDA accelerated approval of fam-trastuzumab deruxtecan-nxki – FDA Oncology
FDA Oncology shared a post on X about a paper titled “FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations” published in The Oncologist Journal.
Authors: Gautam U Mehta, Paz J Vellanki, Yi Ren, Anup K Amatya, Pallavi S Mishra-Kalyani, Lili Pan, Jeanne F Zirkelbach, Yuzhuo Pan, Jiang Liu, Stephanie L Aungst, Claudia P Miller, Mirat Shah, Nam Atiqur Rahman, Marc Theoret, Paul Kluetz, Richard Pazdur, Julia A Beaver, Harpreet Singh.
“OCE’s Gautam Mehta and colleagues summarize the FDA accelerated approval of fam-trastuzumab deruxtecan-nxki—the first targeted treatment option for patients with HER2-mutated non-small cell lung cancer – via The Oncologist Journal.”
Source: FDA Oncology/X
